Bupropion and Naltrexone Extended-Release Tablets - A Detailed Exploration

Overview:

The combination of Bupropion and Naltrexone, together with a low-calorie diet and exercise routine, is used to help patients shed weight or prevent relapse in people who are overweight and have medical conditions related to their weight. These drugs decrease appetite and aid in controlling cravings by acting on the brain's reward system and the hunger region. The FDA (Food and Drug Administration) approved the drug in 2014.

Drug Group:

Naltrexone belongs to a group of drugs known as opiate antagonists. Bupropion is a member of the class of medications referred to as antidepressants.

Available Doses and Dosage Forms:

In the first week of Bupropion and Naltrexone extended-release tablets, dosing consists of one tablet taken in the morning. In the second week, it is taken in the evening as well, and by the fourth week, the dosage is progressively increased to two tablets taken twice a day. It is not crushed or crushed and is consumed orally. It should not be taken with a high-fat meal. It is important to monitor heart rate and blood pressure, particularly in people with hypertension. Assessing the therapeutic response at the maintenance dosage after 12 weeks is recommended. It is improbable that a patient who has not shed less than five percent of their baseline body weight will achieve and maintain clinically relevant weight loss with prolonged treatment. As such, discontinue giving them extended-release Naltrexone and Bupropion tablets.

For Patients:

What Is Obesity?

Obesity is a complex disorder that can lead to significant body fat and, on occasion, poor health. Being overweight by itself does not cause disease. Excess body fat, however, may change the way the body works. These changes are slow-moving, could deteriorate over time, and could be harmful to one's health.

A health issue raises the possibility of numerous other illnesses and conditions. These can include sleep apnea, diabetes, liver disease, high blood pressure, high cholesterol, heart disease, and some types of cancer. Many factors can contribute to an individual's inability to reduce weight. Genetic, physiological, and environmental variables and diet, exercise, and physical activity decisions frequently cause obesity.

How Do Bupropion and Naltrexone Extended-Release Tablets Work?

Bupropion and Naltrexone reduce appetite and help control cravings by acting on the brain's reward system and the hunger region.

What Are the Things to Inform the Doctor Before Taking the Drug?

• Allergies and Interactions: Let the doctor know if a person has allergies to Bupropion, Naltrexone, or other drugs. Avoid taking MAO (monoamine oxidase) inhibitors or opioids concurrently with Naltrexone and Bupropion, as it can lead to severe reactions or reduced effectiveness.

• Opioid Sensitivity: Naltrexone prevents the effects of opioids. Taking opioids through the treatment or after withdrawal can lead to severe problems, overdose, or death due to heightened sensitivity.

• Medication and Substance Interactions: Be cautious when using Bupropion in combination with other products, as it may have serious negative effects. All prescriptions, over-the-counter medications, herbal supplements, and vitamins should be disclosed to the doctor to avoid any possible drug interactions.

• Health Conditions: Let the doctor know about any history of seizures, eating disorders, uncontrolled hypertension, mental health problems, substance abuse, suicidal thoughts or attempts, and other ailments like diabetes, renal, liver, or heart disease.

• Pregnancy and Surgery: Let the doctor know if a person intends to get pregnant, is already nursing a baby, or is having surgery. During this time, discuss the advantages and disadvantages of using Bupropion and Naltrexone.

• Drinking Alcohol: While taking this drug, alcohol use should be discussed with the doctor as it may intensify negative effects.

• Monitoring: Since the medicine may cause an increased heart rate and blood pressure along with an increased risk of angle-closure glaucoma, it is important to routinely monitor blood pressure and heart rate and conduct eye exams.

How Are Bupropion and Naltrexone Extended-Release Tablets Administered?

An oral extended-release (long-acting) tablet containing both Bupropion and Naltrexone is available. Usually, two doses per day are given. Take this drug without a high-fat meal. Take Bupropion and Naltrexone daily at approximately the same times. Ask the pharmacist or doctor to clarify anything that is unclear. Take Bupropion and Naltrexone precisely as prescribed. Take it exactly as suggested by the doctor. Do not take it more or less frequently. The extended-release pills should be swallowed whole. Do not break, chew, or crush them.

What Are the Side Effects of Bupropion and Naltrexone Extended-Release Tablets?

• The common adverse effects include increased sweating, flushing, dry mouth or an odd taste in the mouth, nausea, vomiting, constipation, stomach pain, headache, dizziness, and difficulty sleeping. Notify the physician if problems continue or get worse.

• Serious side effects are uncommon, including tremors, ringing in the ears, fainting, fast or irregular heartbeat, chest discomfort, and mental or emotional problems (agitation, disorientation, anxiety, memory loss).

• Seizures are an uncommon side effect of Bupropion. It is advisable to stop using Bupropion if a seizure happens while taking it.

• Naltrexone can cause serious liver damage at larger doses. A persistent nausea attack, vomiting, appetite loss, severe stomach pain, yellowing of the eyes or skin, or black urine are symptoms to be aware of. If these symptoms appear, immediate medical assistance is required.

• Even though severe allergic reactions are uncommon, one should still get medical attention immediately if they experience any symptoms, including swelling of the tongue, neck, or face, itching, rashes, and breathing difficulties.

Dietary Considerations:

Unless the doctor instructs differently, it is advised to continue eating normally while taking this medication.

Missed Dose:

If a dose is missed, it is best to go on with the usual dosing plan without missing the missed dose. It is not advisable to double up on dosages to catch up. Rather, the subsequent prescribed dosage should be taken at regular intervals.

Overdose:

It is critical to immediately contact emergency personnel and the doctor if the person passes out, has seizures, has trouble breathing, or does not respond. Seizures, hallucinations (the seeing or hearing of unreal objects), lack of consciousness, or a rapid heartbeat are all possible indications of an overdose. It is crucial to seek medical attention right away if these symptoms appear.

Storage

The medicine should not be kept in the restroom. It should be kept at room temperature and away from light and moisture. To ensure their safety, keep any drugs out of the reach of children and pets. When a product expires or is no longer needed, dispose it properly. Speak with a nearby waste disposal business or pharmacy for advice on appropriate disposal techniques.

For Doctors:

Indication:

For the long-term management of weight in adults with an initial body mass index (BMI) of 30 kg/m2 (kilogram per square meter) or higher (obesity) and in overweight patients with a BMI of 27 kg/m2 or higher (overweight) and at least one weight-related comorbidity, such as diabetes mellitus or hypertension, Naltrexone and Bupropion are prescribed in conjunction with increased physical activity and a low-calorie diet.

Dosing Considerations:

For the first week of extended-release Bupropion and Naltrexone pills, the recommended dosage is one tablet given first thing in the morning. It is also taken in the evening during the second week.

At the start of week four, the daily dosage of Bupropion and Naltrexone extended-release tablets is two tablets twice a day, making it 8 mg of Bupropion and 90 mg of Naltrexone, and a total of 360 mg of Bupropion and 32 mg of Naltrexone.

What Are the Pharmacological Aspects of Bupropion and Naltrexone Extended-Release Tablets?

• Description - Bupropion and Naltrexone extended-release tablets are available for oral administration. The shape of the tablet is round and biconvex. Every tablet comprises a trilayer core comprising two medicine layers that hold the drug and excipients and an inert layer that dissolves more quickly between them. There are 8 mg of Naltrexone hydrochloride and 90 mg of Bupropion hydrochloride in each tablet.

The inactive ingredients present in each tablet are L-cysteine hydrochloride, lactose anhydrous, microcrystalline cellulose, hydroxypropyl cellulose, edetate disodium, magnesium stearate, hypromellose, crospovidone, lactose monohydrate, Opadry II Blue and FD&C Blue #2 aluminum lake, colloidal silicon dioxide, and crospovidone.

• Pharmacodynamics: Bupropion and Naltrexone extended-release tablets increased the activity of hypothalamic proopiomelanocortin (POMC) neurons related to regulating hunger, leading to reduced appetite.

• Mechanism: Based on nonclinical research, Naltrexone and Bupropion may affect two distinct brain regions that regulate food intake: the mesolimbic dopamine circuit (a reward system) and the hypothalamus (the area responsible for regulating appetite). It is unclear exactly what neurochemical changes are caused by Bupropion and Naltrexone extended-release tablets that result in weight loss.

Pharmacokinetics

• Naltrexone

  • Absorption: Two hours after ingesting Bupropion and Naltrexone extended-release tablet, the maximal Naltrexone concentration was reached.

  • Food Effect: Naltrexone exposure was considerably elevated by high-fat diets.

  • Distribution: Naltrexone has a wide range of distribution volumes and is weakly bound to plasma proteins.

• Excretion and Metabolism: The metabolic compound is classified as 6-beta-Naltrexone, primarily eliminated by the kidneys. The half-life of elimination is about five hours.

• Bupropion

  • Absorption: Three hours were needed for the peak concentration.

  • Food Effect: Bupropion exposure was somewhat elevated by high-fat meals.

  • Distribution: Compared to Naltrexone, Bupropion has a lower volume of distribution while being well-linked to plasma proteins.

  • Excretion and Metabolism: Metabolites are converted into active chemicals and primarily eliminated through feces and urine. The half-life of elimination is roughly twenty-one hours. When doses are repeated, metabolites build up over a week.

Clinical Studies:

4536 individuals were enrolled in four phase 3 trials, COR-I, COR-II, COR-BMOD, and COR-Diabetes, to evaluate the safety and effectiveness of Bupropion and Naltrexone extended-release tablets for weight loss. Three trials examined obesity or obesity under controlled conditions; COR-Diabetes examined patients with type-2 diabetes who were overweight or obese. Lifestyle modification counseling was provided in all the trials; however, COR-BMOD was provided more extensive counseling.

Patients consistently lost a considerable amount of weight throughout all trials compared to placebo. Weight loss persisted for the full 56-week period. Participants in COR-BMOD, who underwent more extensive lifestyle changes, lost much more weight. These results show how lifestyle modifications impact the medication's effectiveness and long-term durability in reducing weight.

What Are the Contraindications of Bupropion and Naltrexone Extended-Release Tablets?

Patients on Bupropion-containing medicines, those with eating disorders, chronic opioid users, acute opiate withdrawal, or those with uncontrolled hypertension should not use Bupropion and Naltrexone extended-release tablets. Patients with seizure disorders or a history of seizures should also not use Bupropion and Naltrexone extended-release tablets. It should not be taken with MAOIs or concurrently with alcohol, benzodiazepines, barbiturates, or antiepileptic medications. It should also be avoided during pregnancy and in people with a history of adverse reactions to Bupropion or known allergies.

Warnings and Precautions:

• Suicidal Behavior and Idea: Bupropion is used in antidepressants. During clinical investigations, it was found that a small percentage of the study population who consumed antidepressants like Bupropion developed suicidal thoughts or attempts. Minors younger than 18 are not authorized to use Naltrexone and Bupropion together. Antidepressants have raised concerns because they can worsen depression or trigger suicidal thoughts, especially in the early stages of treatment. The caregivers and family members of patients on Bupropion or any antidepressants should be made aware of the need to keep an eye out for warning signs such as agitation, anxiety, irritability, strange behavioral changes, and the onset of suicidal thoughts. Reporting any such symptoms to medical professionals right away is advised. It is advised to monitor continuously.

• Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation Treatment: Although Bupropion and Naltrexone extended-release tablet is not authorized for stopping smoking, some patients who have been using Bupropion to do so have experienced severe neuropsychiatric side effects. These include psychosis, hallucinations, paranoia, delusions, homicidal ideas, anger, agitation, aggression, anxiety, panic attacks, and suicidal thoughts or acts. Mood swings such as sadness and mania are also included. Patients should closely observe these responses; medical personnel should be notified if symptoms appear.

• Seizures: Bupropion has a dose-related seizure risk that is impacted by several patient-related characteristics and concomitant drugs that reduce the threshold for seizures. These hazards must be carefully evaluated before starting Bupropion and Naltrexone extended-release tablets. The drug should not be administered to people who have a history of anorexia nervosa or bulimia, have seizures, or are going through abrupt withdrawal from alcohol, benzodiazepines, barbiturates, or antiepileptic medications. Patients with a history of head trauma, previous seizures, severe stroke, disorders of the central nervous system, metabolic problems, excessive alcohol or sedative use, stimulant addiction, or sedative withdrawal should be prescribed Bupropion and Naltrexone extended-release tablets with caution. Careful monitoring is necessary for diabetic patients taking insulin or some oral medicines that can cause hypoglycemia. The medicine should also be used with caution in combination with other drugs that may lower the seizure threshold, such as antipsychotics, Theophylline, tricyclic antidepressants, other Bupropion compounds, or systemic steroids.

• Allergic Reactions: Bupropion has been connected to uncommon allergic reactions that include urticaria, pruritus, angioedema, and dyspnea. There have been reports of severe illnesses such as anaphylactic shock, Stevens-Johnson syndrome, and erythema multiforme. When allergic symptoms appear, patients should stop using Bupropion and Naltrexone extended-release tablets and immediately get a doctor's help.

• Activation of Mania: In people who have bipolar illness or are at risk for it, treatment with Bupropion and Naltrexone extended-release tablets may cause manic or hypomanic episodes due to the presence of Bupropion, which is an antidepressant. Therefore, before starting treatment, ask patients about their history of bipolar disorder or risk factors.

• Hepatotoxicity: Naltrexone has been associated with abnormal liver functioning and hepatitis. Thus, patients should be informed about the risk of liver injury before they are prescribed Bupropion and Naltrexone extended-release tablets. Medical attention should be asked as soon as the first signs appear.

• Hypoglycemia: Due to the possible risk of hypoglycemia from weight loss, patients with type 2 diabetes who use insulin or insulin secretagogues should check their blood glucose levels before and throughout treatment with Bupropion and Naltrexone extended-release tablets. To properly control hypoglycemia, non-glucose-dependent antidiabetic drugs may need to be adjusted. A patient's antidiabetic medication regimen should be adjusted if hypoglycemia occurs.

• Angle-Closure Glaucoma: In people with narrow eye angles who do not have iridectomy, dilating the pupils brought on by some antidepressants, such as Bupropion, may produce an angle-closure attack.

What Are the Drug Interactions of Bupropion and Naltrexone Extended-Release Tablets?

• MAOI: It is not recommended to take Bupropion and MAOIs simultaneously. When Bupropion is taken alongside medications that also prevent dopamine or norepinephrine from being reabsorbed, such as monoamine oxidase inhibitors (MAOIs), the possibility of hypertensive responses increases. The interval between stopping an MAOI and starting Bupropion and Naltrexone extended-release tablets medication should be at least 14 days and vice versa.

• Opioid Analgesics: Treatment with opioid-containing medications, such as cough and cold treatments, antidiarrheal medications, and opioid analgesics, may not be completely beneficial for patients on Bupropion and Naltrexone extended-release tablets. It should be temporarily stopped in patients who require intermittent opiate treatment, and the dosage of opiate medication should not be increased above the recommended level. To avoid precipitating withdrawal symptoms, Bupropion and Naltrexone extended-release tablets should be used cautiously after stopping long-term opioid use for seven to ten days.

• Drugs Metabolized by CYP2D6 - Drugs metabolized by CYP2D6 such as beta-blockers, antipsychotics, and some antidepressants) should be used with caution in people receiving treatment with Bupropion and Naltrexone extended-release tablets because of possible interactions that necessitate lower starting doses. Drugs with limited therapeutic ranges could require adjustments.

• Alcohol Use: To avoid neuropsychiatric episodes or decreased alcohol tolerance, minimize or avoid alcohol during Bupropion and Naltrexone extended-release tablets treatment.

• Dopaminergic Drugs: Since Bupropion and Naltrexone extended-release tablets may have additive dopamine effects, it is important to watch for central nervous system (CNS) toxicity while taking it in combination with Levodopa or Amantadine.

• Drugs That Lower Seizure Threshold: When taking Bupropion and Naltrexone extended-release tablets with other medications that reduce seizure thresholds, such as antidepressants or antipsychotics, start with small doses and gradually increase them. It is not recommended to take other products containing Bupropion concurrently.

• Drug-Laboratory Test Interactions: Patients on Bupropion have been documented to have false-positive results from urine immunoassay screening tests for Amphetamines. Even after stopping Bupropion therapy, false-positive test results can still occur. Bupropion will be distinguished from amphetamines by doing confirmatory testing, such as gas chromatography/mass spectrometry.

Specific Considerations:

• Pregnancy: Bupropion and Naltrexone extended-release tablets are not advised during pregnancy. Considering that weight loss has no possible benefits for pregnant women and may harm the fetus, the patient should be informed of the possible risk of maternal weight loss to the fetus if this medication is used during pregnancy or if the patient gets pregnant while taking it.

• Lactating Mothers: Human milk has been demonstrated to contain the components and metabolites of Bupropion and Naltrexone extended-release tablets. Oral Naltrexone has been shown to transfer 6-beta-Naltrexol and Naltrexone into human milk. Human milk also secretes Bupropion and its metabolites. Nursing moms are not advised to use Bupropion and Naltrexone extended-release tablets.

• Pediatric Population - Bupropion and Naltrexone extended-release tablets are not recommended for use in pediatric patients since their safety and efficacy in treating individuals under 18 have not been shown.

• Geriatric Population - There is insufficient information to determine the effects on the senior age group. Adverse effects of a higher sensitivity to the central nervous system may exist in older persons. Since the kidneys are the organs that remove both Bupropion and Naltrexone, care should be taken when dealing with those who have reduced kidney function, particularly the elderly. Careful dosage selection and possible renal function monitoring are recommended for those over 65.

• Hepatic Impairment - No research has been done on Bupropion and Naltrexone extended-release tablets in liver disease patients. On the other hand, evidence on its constituents indicates a markedly increased exposure in individuals with moderate-to-severe hepatic impairment. Bupropion and its metabolites by two to three times, and Naltrexone and its metabolites by up to ten times. The maximum daily dosage of Bupropion and Naltrexone extended-release tablets for individuals with hepatic impairment is one tablet taken in the morning.

• Renal Impairment - No specific study on Bupropion and Naltrexone extended-release tablets for renal disease patients. In moderate-to-severe kidney impairment, however, data on its components indicate higher exposure. A daily maintenance dose of two tablets (one in the morning and one in the evening) is advised in case of moderate to severe renal issues. People with serious kidney conditions should not use it. For mild renal problems, there is no recommended dosage.